Why the Starpharma share price is pushing higher today

Here's why the Starpharma Holdings Limited (ASX:SPL) share price is pushing higher on Monday morning…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Starpharma Holdings Limited (ASX: SPL) share price is pushing higher on Monday.

In morning trade the dendrimer products developer's shares are up 2% to $1.22 following an announcement.

What did Starpharma announce?

This morning Starpharma announced that pharma giant AstraZeneca has commenced a phase 1 clinical trial of AZD0466 and the first patient has been successfully dosed.

According to the release, the trial will recruit patients with a range of cancers and will be conducted at up to five US sites.

The development of AZD0466 is being progressed under a multi-product license. This means Starpharma is eligible to receive development, launch, and sales milestones of up to US$124 million. Furthermore, it will receive tiered royalties on net sales if the product reaches that stage.

Milestone payment.

The release advises that the first dose of AZD0466 administered in the phase 1 trial has triggered a milestone payment to Starpharma of US$3 million.

This could be the first of many based on AstraZeneca's comments. It has described AZD0466 as having the potential to be a best-in-class agent in this field with a broad opportunity in solid and haematological tumours (blood cancers) due to its ability to target both Bcl2 and Bcl/xL1.

Bcl2 is a clinically validated oncology target. The Bcl2 inhibitor, venetoclax, was approved by the US FDA in 2016 and has estimated peak global sales projected to be between US$2 billion to US$3 billion.

Starpharma CEO, Dr Jackie Fairley, said: "It is really exciting to achieve this important milestone both for our collaboration with AstraZeneca and for Starpharma's DEP platform."

"This is our first partnered DEP product to enter the clinic, alongside our three internal DEP products, DEP docetaxel, DEP cabazitaxel and DEP irinotecan. AZD0466 is a great illustration of the benefits that can be created for novel agents using Starpharma's DEP platform and we look forward to further updates as the trial progresses," she added.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Starpharma Holdings Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

These were the best-performing ASX 200 shares in March

These shares made their shareholders smile in March thanks to some very big gains.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Share Gainers

3 ASX All Ords shares up 50%+ in March

These ASX shares have been on fire this month. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Share Gainers

Why Mesoblast, Patriot Battery Metals, Sigma, and Zip shares are pushing higher

These shares are having a good session on hump day. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Consumer Staples & Discretionary Shares

If you'd put $20,000 in this ASX retail stock at the start of 2023, you'd have $134,000 now

This online retailer has executed a remarkable turnaround for its investors.

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was back to earth for ASX shares this Tuesday.

Read more »